董事长：吴海明 二〇二五年八月二十一日 公司董事会、监事会及董事、监事、高级管理人员保证半年度报 告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 公司负责人吴海明、主管会计工作负责人张斌及会计机构负责人 （会计主管人员）顾叶倩声明：保证本半年度报告中财务报告的真实、 准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 浙江震元股份有限公司 浙江震元股份有限公司 | 二、报告期内公开披露过的所有公司文件的正本及公告的原稿。 | | | | --- | --- | --- | | | | 释 义 | | 释义项 指 | | 释义内容 | | 本公司/公司/ | | | | 指 | | 浙江震元股份有限公司 | | 浙江震元 | | | | 震元健康集团 | | 指 绍兴震元健康产业集团有限公司，为公司控股股东。 | | | | 绍兴市人民政府国有资产监督管理委员会，为公司实际 | | 绍兴市国资委 | | 指 | | | | 控制人。 | | 震元制药 指 | | 浙江震元制药有限公司，为公司全资子公司。 | | 震元生物 指 | | 浙江震元生物科技有限 ...

Group 1 - The company plans to issue A-shares to specific investors, pending approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission (CSRC) [2][3][4] - The final issuance price will be no less than 85% of the average trading price of the company's shares over the 20 trading days prior to the pricing date [3][4][5] - The total number of shares to be issued will not exceed 25% of the company's total share capital, amounting to a maximum of 83,530,821 shares [5][6] Group 2 - The funds raised will be allocated to specific projects, including the construction of a production base for amino acids and an enhancement project for raw materials [6][7] - The company may adjust the investment priorities and amounts based on the actual net amount raised and project urgency if the net proceeds are less than planned [6][7] - The company has committed to using the raised funds in compliance with relevant regulations and will replace any pre-invested funds once the raised funds are available [6][7] Group 3 - The company operates in the pharmaceutical industry, which is subject to strict regulatory oversight from various government bodies, including the National Medical Products Administration and the National Healthcare Security Administration [19][20] - The pharmaceutical industry is characterized by significant competition and regulatory challenges, including drug approval processes and pricing regulations [19][20][21] - The company’s business encompasses pharmaceutical distribution, manufacturing, and health services, with a focus on both commercial and industrial sectors [19][20]